We are international

ASH 2011: Dr. San Miguel - Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
Jesús F San Miguel, MD PhD
Hospital Clinico Universitario
Salamanca, Spain

To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

 related articles